Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir

BACKGROUND: Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Si...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz-Gracia, Alba, Ríos, María, Tobías, Ester, Noguera-Julian, Antoni, García-García, Francesc Josep, Cantó-Santos, Judith, Valls-Roca, Laura, Garrabou, Glòria, Grau, Josep Maria, Cardellach, Francesc, Sánchez, Emilia, Morén, Constanza, Fortuny, Clàudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Drug Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209682/
https://www.ncbi.nlm.nih.gov/pubmed/35288419
http://dx.doi.org/10.1136/archdischild-2021-322996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209682/
https://www.ncbi.nlm.nih.gov/pubmed/35288419
http://dx.doi.org/10.1136/archdischild-2021-322996

Ejemplares similares